Flinton Capital Management’s NovoCure NVCR Stock Holding History

Flinton Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14,196	Closed	-$310K	–	864
2018 Q1	$310K	Hold	14,196	–	–	0.01%	544
2017 Q4	$287K	Hold	14,196	–	–	0.01%	570
2017 Q3	$282K	Hold	14,196	–	–	0.01%	532
2017 Q2	$246K	Hold	14,196	–	–	0.01%	529
2017 Q1	$115K	Hold	14,196	–	–	﹤0.01%	597
2016 Q4	$111K	Buy	+14,196	New	+$114K	﹤0.01%	578

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Flinton Capital Management's NVCR Position: Q2 2018 in Review

Flinton Capital Management sold out of NovoCure (NVCR) in Q2 2018, closing a stake of 14,196 shares — an estimated $310K sold.

Flinton Capital Management first reported a position in NVCR in Q4 2016 and held it in 6 quarters. The position peaked at $310K in Q1 2018. 161 funds tracked by Wall St. Rank hold NVCR as of Q2 2018.

Flinton Capital Management reported no remaining NovoCure position as of Q2 2018 after selling out during the quarter.
Flinton Capital Management sold 14,196 NovoCure shares in Q2 2018, an estimated $310K.
Flinton Capital Management first reported a position in NovoCure in Q4 2016 and held it in 6 quarters.
Flinton Capital Management's NovoCure position peaked at $310K in Q1 2018.
161 funds tracked by Wall St. Rank held NovoCure as of Q2 2018.

Based on Flinton Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.